The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 07, 2020

Filed:

Jul. 27, 2018
Applicant:

Adocia, Lyons, FR;

Inventor:

You-Ping Chan, Ternay, FR;

Assignee:

ADOCIA, Lyons, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/22 (2006.01); A61K 38/28 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 9/08 (2006.01); C07K 14/62 (2006.01); A61K 45/06 (2006.01); A61K 38/26 (2006.01); A61K 33/30 (2006.01); A61P 3/08 (2006.01); A61K 38/17 (2006.01); A61K 47/10 (2017.01); A61K 47/20 (2006.01); A61P 5/48 (2006.01); A61P 3/10 (2006.01); A61K 47/12 (2006.01);
U.S. Cl.
CPC ...
A61K 38/28 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 33/30 (2013.01); A61K 38/17 (2013.01); A61K 38/22 (2013.01); A61K 38/26 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01); A61P 3/08 (2018.01); C07K 14/62 (2013.01); A61K 47/12 (2013.01); A61P 3/10 (2018.01); A61P 5/48 (2018.01);
Abstract

A composition in the form of an injectable aqueous solution, with pH from 3.5 to 4.4, including at least human insulin A21G and at least one glucagon suppressor with prandial action. In an embodiment, the glucagon suppressor with prandial action is selected from an amylin analog or an amylin receptor agonist or a GLP-1 analog or a GLP-1 receptor agonist (GLP-1 RA). In an embodiment, the glucagon suppressor with prandial action is an amylin analog or an amylin receptor agonist. In an embodiment, the glucagon suppressor peptide with prandial action is pramlintide. Also, a method for obtaining human insulin A21G, includes at least one step of reacting human insulin A21G, B31R, B32R (insulin glargine) with rat carboxypeptidase B at an insulin/carboxypeptidase ratio from 500 to 2000, at a pH from 7.5 to 8.5 and a temperature from 20 to 30° C. for 10 to 20 hours.


Find Patent Forward Citations

Loading…